Search 

Alykomed Global Solutions LLC (AGSL), based in New York, is a respected and established provider of strategic personalized corporate solutions to the Biopharma industry. Our clients embody a wide range of companies, from innovative startups to larger established, public companies. Our projects include global business development, financial, investment, and capital support, and scientific based endeavors, among others. We are committed to our clients’ long term success, optimized growth strategies, and profitability potential.

We proudly apply our deep scientific knowledge, and combine this with our strong corporate and business development experience and an extensive scientific/business network. Our established and trusted financial investment banking service/registered broker partner, provides our clients with targeted capital and financial solutions and extensive access to institutional and retail investors. These capital services cover a wide range of investment opportunities and offerings, including, but not limited to IPOs and securities offerings, private placements, mergers and acquisition, bank and debt financing etc.

We also undertake strategic growth initiatives through global business development, researching scientific and drug development platforms, assisting with internal valuations, or assistance with other projects- we offer knowledge, experience, leadership, global awareness, and creativity. We work with a global network of professionals, having done business in North America, UK/Europe, and Asia, especially within the United States, Japan, South Korea, and China.

Contract regulatory and clinical research services, U.S. HQ with satellite offices in Taiwan and Europe.
FDA, EMA, etc. worldwide regulatory approval services for drugs, devices, and diagnostics.
Worldwide clinical testing for safety and efficacy

AnGes is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of gene-based medicines including gene therapy, oligonucleotide drugs and DNA vaccines.
The company's lead product is Collategene for critical limb ischemia (CLI), the severest form of peripheral arterial disease (PAD), for which obtained conditional approval in Japan on March 2019. Collategene is a gene therapy product utilizing therapeutic angiogenesis by hepatocyte growth factor (HGF) gene expression. Our second project is NF-kB decoy oligonucleotide, for which a phase 1b study for low back pain commenced in February 2018 in the US. AnGes also conducting a phase I/II study for DNA vaccine for the treatment of hypertension.
We are also developing a DNA vaccine for COVID-19 which we plan to start Phase 3 from early next year.

Aphios®, which means “virus-free” in Greek, is an emerging growth biotechnology company developing green enabling technology platforms for improving drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety in an environmentally-sustainable manner, and enhanced therapeutics for the treatment of infectious diseases, CNS disorders, cancers and supportive care.

Our lead product is Zindol® which has successfully completed a Phase 2/3 clinical trial as an adjuvant to conventional 5-HT3 anti-emetics in cancer patients undergoing chemotherapy. Other clinical products under development are APH-0812 for HIV latency and APH-1104 for Alzheimer’s disease. We have several preclinical leads in development for prostate, breast and pancreatic cancer, cancer pain and infectious diseases.

Our lead platform is CFI™ for the manufacture of virus-free biologics such as convalescent COVID-19 plasma, human plasma proteins and monoclonal antibodies as well as viral vaccines against influenza. Our drug discover discovery platform is being harnessed to develop antiviral therapeutics against the novel coronavirus and our nanotechnology platforms are being used to improve the delivery of HIV latency and Alzheimer’s disease therapeutics.

We are raising capital to conduct pivotal Phase 3 clinical trials of Zindol® for CINV to complete clinical development of Zindol and file an NDA with the FDA. In subsequent financings, which will include an IPO, we plan to raise an additional capital to commercialize Zindol® for CINV and develop other indications.

Aposave is the global pharmaceutical and healthcare services division of the Abacus Medicine Group.

The company mission is to assist patients with unmet medical needs get access to innovative new medicines, while assisting the manufacturers to maximise the clinical and commercial potential of their assets.

Our promise to healthcare and pharmaceutical customers is to provide a new generation of healthcare and pharmaceutical services to support their new generation of pharmaceutical products throughout the 2020’s and beyond.

To do this Aposave has developed a market leading range of services focused on providing access to medicines around the world. Working across the lifecycle in partnership with pharmaceutical and biotechnology companies Aposave creates and delivers innovative solutions that ensure patients can get timely access to the medicines they need, whilst helping pharmaceutical and biotechnology companies achieve their clinical and commercial objectives.
Aposave has a range of services to support the efficient running of clinical trials called Clinical Trial Solutions (CTS). This is an area where there are great synergies with our parent company, Abacus Medicine. The Abacus Medicine Group holds over 4500 marketing authorisations, and this provides Aposave with unrivalled access to the medicines required to support the running of clinical trials. In addition, Aposave has developed some unique approaches to minimising wastage of products that have expired or are no longer required for a trial.
Aposave has extensive knowledge and experience in managing the distribution of specialty medicines, and this service line is called Specialty Commercial Distribution (SCD). Higher value, lower volume specialty medicines often do not sit well with the traditional distribution model, and this is where our team of experts develop innovative solutions to help ensure patients have access, while maintaining the commercial requirements of our clients.
Aposave is a strategic partner to the pharmaceutical and biotech industry. Aposave Access Programs (AAP) provide a framework for a partnership where Aposave creates, implements, and manages a program on behalf of a drug manufacturer to provide access to their drug in countries where it is not commercially available. This can be either in the prelaunch, or the post launch stage of the product lifecycle. Each program is designed to meet the specific needs of the manufacturer.
The final service that Aposave provides is very much focussed on the patient, and as such is called Individual Access Requests (IAR). Patients with an unmet medical need often require access to a medicine that is not commercially available in the country where they live. When the customer service team at Aposave receive such a request from a healthcare professional, if we do not already have the product in stock, we find a source of the product and ensure we deliver it, in compliance with appropriate regulations, to the relevant medical establishment ready for the patient to receive treatment.

We are a European oncology start-up developing an entirely novel platform of small molecule drugs to cure currently untreatable cancers.We wholly own a pipeline of molecules that are active via novel mechanisms in cancer and several other therapeutic areas.
The mechanism of action of our lead drug, Ag5, targets cancer cells generating high levels of Reactive Oxygen Species (ROS). High ROS tumours are, in general, untreatable. This group of cancers includes KRAS-mutation driven cancers, which comprise around 30% of all cancer cases, and the worst prognosis group. There is currently no treatment for KRAS mutant cancers, which lead to more than 1 million deaths worldwide every year.
Glioblastoma Multiforme (GBM), the commonest primary brain cancer, is also a high-ROS cancer, despite the absence of mutated KRAS. There have been no new treatment options in GBM for 20 years, and prognosis is poor-averaging 18 months.
We have a follow-on compound and a pipeline of innovative molecules addressing both cancer and non-cancerous conditions.
We are raising a series A round which will allow us to gain clinical proof of concept.

Articulate Labs builds wearable medical devices amplify muscle growth throughout everyday activity to help others conquer functional limitations and to restore physical capability

Astrom Research International is a CRO consultancy focusing on Life Science between China and Europe.

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.

Top tier Pharmaceutical company in China with leading position in cardiovascular, diabetes, women healthcare, oncology.